From 31 May till 4 June 2024: HIGHLIGHTS FROM ASCO – LUNG CANCER
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2024 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Daily highlights in lung cancer
Dr Lizza Hendriks, a respiratory oncologist at the Maastricht University Medical Center (Netherlands), highlights four significant presentations on NSCLC from ASCO 2024 relevant to clinical practice.
A noteworthy presentation at
Dr Charlotte De Bondt, thoracic oncologist at GZA Hospitals, Antwerp presents her selection of highlights from the rapid oral abstract session on lung cancer. Dr Jonathan Spicer presented a four-year
Dr Dieter Stevens, a thoracic oncologist at University Hospitals Gent in Belgium, shares key findings from ASCO2024 on advanced or metastatic NSCLC patients with rare oncogenic alterations.
Prof Dr Christophe Dooms, a respiratory oncologist at the University Hospitals Leuven (Belgium), highlights three significant presentations on mNSCLC from ASCO 2024 relevant to clinical practice. The first trial, NRG-LU002,
In-depth stories about lung cancer
Despite significant advancements in treatments for lung cancer, many patients still face challenging side effects, including anxiety, depression, and overall declines in quality of life. Recognising the need for comprehensive
A presentation at ASCO focused on the quality of life of patients undergoing the perioperative regimen of chemotherapy plus pembrolizumab in the Keynote 671 trial. Last year, the EFS and
At the ASCO Congress, the results of a study on a non-invasive tool to assess tumour-infiltrating CD8 T cells from contrast-enhanced CTs using AI approaches were presented. This tool shows
The AEGEAN and Checkmate 77T trials investigated perioperative chemotherapy combined with immunotherapy in patients with resectable non-small cell lung cancer (NSCLC). Previous data showed an improvement in event-free survival (EFS)
The ADAURA trial, which investigated adjuvant osimertinib for patients with resected stage I to III non-small cell lung cancer (NSCLC) with classic EGFR mutations, has provided significant insights into the
In the pivotal, phase III CheckMate 816 study, neoadjuvant nivolumab in combination with chemotherapy was shown to significantly improve the pathological complete response rate (pCR) and event-free survival (EFS) in
Over the last decades, therapeutic advances for patients with limited-stage small-cell lung cancer (LS-SCLC) have been limited. With the current standard of care (i.e., concurrent chemoradiotherapy [cCRT]), the prognosis for
Based on the results of the phase III PACIFIC trial, consolidation therapy with durvalumab has become the standard of care for patients with unresectable stage III NSCLC who did not
Lung cancer poster selection
Professor Wakelee from Stanford, United States, presented the final DFS analysis of the IMpower010 trial at ASCO 2024. IMpower010 is a randomised phase 3 trial investigating adjuvant atezolizumab for patients
The final analysis of the DESTINY-Lung02 trial, a dose-blinded phase 2 randomised controlled trial, compared two dosages of the antibody-drug conjugate trastuzumab deruxtecan in heavily pretreated, biomarker-selected, HER2 mutation-positive, non-small
Prof Christophe Dooms, thoracic oncologist at UZ Leuven and Prof Martin Reck, thoracic oncologist and Head of the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf, Hamburg, Germany, discuss